undamentalytics Newsletter
Sign in

Indivior Pharmaceuticals, Inc. cash flow statement

In fiscal 2025, Indivior Pharmaceuticals, Inc.'s operations generated −$27.0m of cash; it spent $66.0m on capital projects, leaving free cash flow of −$93.0m. It returned $11.0m through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash from operations−4−30036−2796
Depreciation and amortisation161516107
Stock-based pay1621242633
Capital spending58296665
Free cash flow−9−3087−9331
Free cash flow after stock pay−25−329−17−119−2
Share buybacks903317311302
Shares issued23320

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: INDV vs PAHCINDV vs LNTHINDV vs TRLV

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Indivior Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Indivior Pharmaceuticals, Inc.